Physician profile
Scott J Samuelson
NPI 1922288588
$1,691.33
in general payments reported to CMS, 2019-2025
27 companies · $553 in 2025
The $553 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $111 · 2021: $30.30 · 2022: $109 · 2023: $217 · 2024: $530 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $427.53 | 2022-2025 | |
| Beigene USA, INC. | $116.00 | 2023-2024 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $111.38 | 2020 | |
| Glaxosmithkline, LLC. | $95.67 | 2021-2025 | Zejula, Jemperli |
| Bayer Healthcare Pharmaceuticals INC. | $86.33 | 2024-2025 | |
| Medtronic, INC. | $84.09 | 2024 | Intellis Adaptivestim |
| Astrazeneca Pharmaceuticals Lp | $78.35 | 2025 | Imfinzi, Enhertu |
| Janssen Biotech, INC. | $68.20 | 2022-2023 | Darzalex, Tecvayli |
| Emd Serono, INC. | $64.40 | 2024-2025 | |
| Daiichi Sankyo INC. | $63.03 | 2023-2025 | Enhertu |
| Array Biopharma INC | $61.06 | 2025 | Braftovi, Mektovi, Lorbrena |
| Foundation Medicine, INC. | $51.42 | 2019 | |
| Astellas Pharma US INC | $49.99 | 2019-2022 | |
| Genmab U.S., INC. | $48.98 | 2024-2025 | Tivdak |
| Novartis Pharmaceuticals Corporation | $45.00 | 2019-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $43.30 | 2019 | |
| Celgene Corporation | $30.66 | 2024 | Reblozyl |
| Amgen INC. | $26.73 | 2023 | Kyprolis |
| Immunogen, INC. | $25.13 | 2023 | Elahere |
| Abbvie INC. | $22.28 | 2025 | |
| Puma Biotechnology, INC. | $18.53 | 2025 | |
| Seagen INC. | $17.97 | 2022 | |
| Exelixis INC. | $17.03 | 2024 | Cabometyx |
| Genzyme Corporation | $14.11 | 2025 | |
| Genentech USA, INC. | $13.98 | 2023 | Tecentriq |
| Clovis Oncology, INC. | $10.18 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$42,970.81 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Samuelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.